STOCK TITAN
  1. Home
  2. Sec-filings
  3. VNDA
  4. [Form 4] Vanda Pharmaceuticals Inc. Insider Trading Activity

Vanda Pharmaceuticals (VNDA) director receives 41,600-share RSU grant

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Vanda Pharmaceuticals director Honore Tage received a grant of 41,600 shares of common stock through a restricted stock unit (RSU) award. The RSUs are time-based and will vest 100% on June 4, 2027, if Tage continues to provide service to the company through that date.

Following this grant, Tage directly holds 135,069 shares of Vanda Pharmaceuticals common stock. Because the shares were awarded as equity compensation at no cash cost, this filing reflects a compensation-related acquisition rather than an open-market purchase.

Positive

  • None.

Negative

  • None.
Insider Honore Tage
Role null
Type Security Shares Price Value
Grant/Award Common Stock 41,600 $0.00 --
Holdings After Transaction: Common Stock — 135,069 shares (Direct, null)
Footnotes (1)
  1. [object Object]
RSU grant size 41,600 shares Time-based restricted stock unit award to director Honore Tage
Grant price per share $0.00 per share Indicates equity compensation, not an open-market purchase
Shares after transaction 135,069 shares Total Vanda common shares directly held by Honore Tage after grant
Vesting date June 4, 2027 100% of RSU shares vest on this date with continuous service
restricted stock unit award (RSU) financial
"Represents shares of common stock underlying a time-based restricted stock unit award (RSU)."
time-based financial
"Represents shares of common stock underlying a time-based restricted stock unit award (RSU)."
vesting date financial
"through the vesting date."
continuous service financial
"provided that the Reporting Person has provided continuous service to the Issuer through the vesting date."
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Honore Tage
(Last)(First)(Middle)
C/O VANDA PHARMACEUTICALS INC.
2200 PENNSYLVANIA AVENUE, SUITE 300E
(Street)
WASHINGTON DISTRICT OF COLUMBIA 20037
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Vanda Pharmaceuticals Inc. [ VNDA ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/04/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/04/2026A41,600(1)A$0135,069D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on June 4, 2027, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date.
/s/ Tage Honore06/08/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Vanda Pharmaceuticals (VNDA) director Honore Tage report on this Form 4?

Director Honore Tage reported receiving 41,600 shares of Vanda Pharmaceuticals common stock through a restricted stock unit (RSU) grant. The award is equity compensation, not an open-market purchase, and increases Tage’s directly held stake in the company to 135,069 shares.

How many Vanda Pharmaceuticals (VNDA) shares were granted to Honore Tage?

Honore Tage was granted 41,600 shares of Vanda Pharmaceuticals common stock via a restricted stock unit award. These shares carry a vesting schedule, meaning they are not immediately unrestricted and depend on continued service until the specified vesting date.

When do Honore Tage’s Vanda Pharmaceuticals (VNDA) RSUs vest?

All 41,600 restricted stock units awarded to Honore Tage will vest on June 4, 2027. Full vesting is contingent on Tage providing continuous service to Vanda Pharmaceuticals through that date, aligning the director’s compensation with longer-term company performance.

Did Honore Tage buy Vanda Pharmaceuticals (VNDA) shares on the open market?

No, the Form 4 shows a grant of 41,600 restricted stock units with a price per share of $0.00. This indicates an equity compensation award from the company, not an open-market purchase, so no cash outlay or public market trade is involved.

How many Vanda Pharmaceuticals (VNDA) shares does Honore Tage own after this grant?

After the RSU grant, Honore Tage directly holds 135,069 shares of Vanda Pharmaceuticals common stock. This total reflects the director’s position following the award and helps investors gauge the scale of insider ownership relative to the new compensation grant.

What conditions apply to Honore Tage’s Vanda Pharmaceuticals (VNDA) RSU award?

The RSU award represents time-based restricted stock units that vest only if service continues. All 41,600 underlying shares will vest on June 4, 2027, provided Honore Tage has maintained continuous service to Vanda Pharmaceuticals through the full vesting period.